Odyssey Therapeutics has filed for a second attempt at an initial public offering after pulling its first effort a year earlier. The Boston-based biotech submitted its updated IPO paperwork as it seeks a more favorable market window to fund development and advance its clinical pipeline. The relaunch of IPO plans reflects a recurring pattern in biotech financing: companies often time public-market access to periods of improved risk appetite, especially when their lead assets are approaching key readouts. While the summary does not provide details on pricing or size, the move signals renewed investor interest in clinical-stage companies with defined regulatory or clinical catalysts. For stakeholders, the immediate watchpoint will be the company’s ability to translate late-stage execution and milestone planning into underwriting confidence as the offering process progresses.